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Background: Several studies have explored the association between use of 
antidiabetic medication (ADM) such as metformin and insulin on risk of different 
cancer types, but few have analyzed cancer mortality or been able to take into account 
simultaneous use of different ADMs. 
Materials and methods: Our study cohort included 15,892 diabetic men with either a 
recorded diagnosis of diabetes mellitus during 1996-2015 or recorded ADM use during 
the same period. The source population was 78,615 men originally identified for the 
Finnish Randomized Study of Screening for Prostate Cancer. Information on causes of 
death was obtained from national death certificate registry of Statistics Finland. The 
data included dates for death and primary, underlying and contributing causes as ICD-
10 codes. Follow-up for deaths started at FinRSPC randomization and extended until 
the end of 2015. 
Information on ADM purchases during 1995-2015 was obtained from national 
prescription database. Overall cancer mortality and mortality from specific cancer 
types was analyzed using Cox proportional hazards regression model with adjustment 
for age and co-morbidities. ADM usage was analyzed as time-dependent variable to 
avoid immortal time bias. Simultaneous use of different ADM classes was estimated 
by forming time-dependent variable for each class (biguanides, insulin secretagogues 
(sulphonylureas, glinides), thiazolidinediones, insulins and DPP-4 inhibitors). Lag-time 
analyses were used to estimate long-term risk associations. 
Results: Insulin use (HR 2.16, 95%CI 1.95-2.39) and use of insulin secretagogues 
(HR 1.40, 95%CI 1.26-1.56) were associated with elevated cancer mortality 
compared to non-users. A modest risk increase was observed also in users of 
metformin (HR 1.13, 95%CI 1.00-1.28). The mortality increase among users of 
insulin and insulin secretagogues was attenuated, but remained elevated compared 
to non-users after allowing for a latency of 1-3 years.  
Conclusion: Increased cancer mortality among users of insulin and insulin 
secretagogues in a cohort of diabetic men supports the role of hyperinsulinemia as a 
risk factor for cancer death. However, the risk increase attenuated in long-term use, 
suggesting that the underlying diabetes necessitating insulin use may be the cause of 
the risk association.  
 
Avainsanat: diabetes, syöpäkuolleisuus, metformiini, insuliini 
 
Tämän julkaisun alkuperäisyys on tarkastettu Turnitin OriginalityCheck –ohjelmalla. 
 
 
  
6 
 
 
 
  
2 
 
2. Research team 
 
 
 
Mari IA Haikonen1, Kirsi Talala2, Kimmo Taari3, Jorma Lahtela4, Teuvo LJ Tammela1,5, 
Anssi Auvinen6, Teemu J Murtola1,5,7 
 
1 Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland 
2 Finnish Cancer Registry, Helsinki, Finland 
3 Department of Urology, Helsinki University and Helsinki University Hospital, Helsinki, 
Finland 
4 Tampere University Hospital, Department of Internal Medicine, Tampere, Finland 
5 Tampere University Hospital, Department of Urology, Tampere, Finland 
6 University of Tampere, Faculty of Social Sciences, Tampere, Finland 
7 Seinäjoki Central Hospital, Department of Surgery, Seinäjoki, Finland 
 
 
 
 
  
3 
 
2. Introduction 
  
 
 
The relationship between diabetes mellitus and cancer has been investigated 
extensively. Diabetes has been associated with increased cancer incidence and 
mortality[1,2]. On the other hand, antidiabetic medications (ADMs) may affect cancer risk 
and mortality in patients with diabetes[3]. Some ADMs, such as metformin and 
thiazolidinediones are associated with a decreased cancer risk, while others such as 
insulin and sulphonylureas with an increased cancer risk[3-7]. 
Previous studies have reported reduced cancer risk among metformin users[8]. The 
research on cancer mortality has tended to focus on certain ADMs and cancer types.  
Most previous studies have not been able to take into account simultaneous use of 
different ADMs, which may be problematic as these drugs are often used in 
combination, and the drug choice changes during the course of the condition. 
To our knowledge, comprehensive evaluation of cancer mortality among ADM users 
in general and among users of specific ADM groups has not been performed before. 
Therefore, we evaluated overall cancer mortality and risk of death due to most 
common cancer types by ADM use in a population-based cohort of diabetic men from 
the Finnish Randomized Study for Prostate Cancer Screening. 
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4. Materials and methods 
  
 
 
3.1 Study cohort 
  
  
FinRSPC is a randomized trial evaluating effects of prostate specific antigen (PSA)-
based prostate cancer screening, All 55-67 year old men residing in the metropolitan 
areas of Helsinki or Tampere, Finland in 1996-1999 (80,456 men) were identified from 
the Finnish Population Register Centre. Prevalent prostate cancer cases were excluded 
and the remaining 80,144 men were randomized either to be invited to attend PSA 
screening at four-year intervals (31,866 men), or no intervention (48,278 men). Both 
groups were followed through the Finnish Cancer Registry.[9]  
To evaluate effects of antidiabetic drugs among men with diabetes, we limited the 
study population to include only men with either a recorded diagnosis of diabetes (E10 
or E11) during the follow-up (1996-2013) or any recorded antidiabetic drug use during 
that time, resulting in a cohort of 15,892 diabetic men.  
Information on diabetes diagnoses were obtained from the Care Registers for Social 
Welfare and Health Care (HILMO) maintained by the National Institute for Health and 
Welfare. This registry records all diagnoses from in- and outpatient hospital visits in 
Finnish health care units. HILMO data was also used to obtain information on co-
morbidities to calculate Charlson co-morbidity index according to 2011 criteria.[10] No 
information on severity of liver insufficiency was available from HILMO, thus all 
participants with this diagnosis were assumed to have mild liver insufficiency when 
calculating Charlson index. The data from different sources were combined using 
deterministic record linkage using the unique personal identification number as the 
key.  
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Information on dates and causes of deaths was obtained from the Statistics Finland, 
which registers all deaths in Finland. The registry has used the 10th revision of the 
International Classification of Diseases (ICD-10) since 1996. The data included dates 
for deaths and immediate, underlying and contributing causes as ICD-10 codes.  
All deaths with ICD-10 codes C00-D48 registered as the primary cause of death were 
considered to be cancer deaths. Similarly, deaths due to lung cancer (C34), colorectal 
cancer (C18-C20), gastric cancer (C16), pancreatic cancer (C25), liver cancer (C22), non-
Hodgkin lymphoma (C82, C83 and C85), renal cell cancer (C64-C66), bladder cancer 
(C67) and tumors of the brain or the central nervous system (C70-C72) were 
determined separately. 
BMI values were collected through surveys sent with FinRSPC screening 
invitations.[11] Data on BMI was available for 2,352 men. Data on fasting blood 
glucose was available for 4037 men and glycosylated hemoglobin A1c (HbA1c) for 3991 
men from the database of Fimlab, the leading provider of laboratory services in the 
Pirkanmaa region. 
  
 
3.2  Information on antidiabetic medication use 
  
 
The study cohort was linked to the national prescription database maintained by the 
Social Insurance Institution (SII) of Finland to obtain information on ADM purchases 
during the years 1995-2014.  SII is a governmental agency providing reimbursements 
for physician-prescribed medications as a part of the national health insurance. All 
Finnish citizens are entitled to the reimbursement for every purchase of a prescription 
drug approved by the SII. All reimbursed purchases are registered by the prescription 
database. The recorded information for each purchase includes the date, ATC code, 
product number and number of packages. Over-the-counter purchases or drugs used 
during hospital inpatient periods are not re-imbursed nor recorded by the database. 
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Drug strength and number of pills were determined for each purchase. The database 
covers ADMs comprehensively because they are available almost exclusively by 
prescription and approved by the SII.  
Amount of drug use was standardized between different ADMs by calculating the 
drug-specific mg or IU quantity purchased annually and dividing it with the mg/IU 
amount corresponding to drug-specific Defined Daily Dose (DDDs).[12] Duration of 
drug use was calculated as years with any recorded drug purchases, regardless of the 
purchased amount. Average dose per year (intensity of use) was calculated by dividing 
the overall DDD quantity with years of drug use. 
 
 
3.3 Statistical analysis 
 
  
 Overall risk of cancer death and risk of death from specific cancer types was analyzed 
using Cox proportional hazards regression model to calculate hazard ratios (HRs) and 
95% CI intervals (95% CI). Follow-up started at the date of the screening trial 
randomization in 1996-1999 and was continued until death, emigration from Finland 
or January 1, 2015 whichever came first. 
In statistical analysis, every ADM subgroup (metformin, sulphonylureas, 
thiazolidinediones, insulines and others including gliptins and glinides) was treated as 
a separate variable to evaluate independent effects and also to model simultaneous 
use of ADMs. 
We used age-adjusted and multivariable adjusted models. The multivariable-adjusted 
model included use of statins, antihypertensive drugs and use of aspirin or other 
NSAIDs. 
Status of ADM drug use as well as quantity, duration and average yearly dose were 
time-dependent variables, updated prospectively for each follow-up year according to 
registered drug purchases. 
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Latency in effects of ADM use was examined in lag-time analyses, in which the 
exposure was lagged 1-3 years forward in the follow-up; for example, drug purchases 
in 2004 were analyzed on 2005 in one-year lag-time analysis.  
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5. Results 
 
 
4.1 Population characteristics 
  
 
The study population included 15,892 diabetic men, of whom 12,440 (78.3%) had ever 
used metformin, 6,270 (39.5%) insulin, 8,226 (51.1%) insulin secretagogues and 1,819 
(11.4%) thiazolidinediones. Numbers of men who had used more than one drug group 
are shown in Figure 1. During median follow-up of 17 years, there were 1,688 cancer 
deaths (1,062/10,000; 10.6% of the cohort), of which 1,232 (990/10,000) occurred in 
metformin users, 775 in users of insulins (1236/10,000), 1,007 in users of insulin 
secretagogues (1224/10,000) and 165 in users of thiazolidinediones (907/10,000).  
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Figure 1. Numbers of users of each antidiabetic drug group. Study population 
of 15,892 diabetic men from the Finnish Randomized Study of Screening for 
Prostate Cancer 
 
The median age at baseline did not differ between users of different drug groups. The 
median BMI was higher among users of metformin or thiazolidinediones compared to 
users of insulin or insulin secretagogues, and they had more often used also statins 
and NSAIDs (Table 1). Nevertheless, the median Charlson co-morbidity score was 
higher among users of insulin and insulin secretagogues. 
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Table 1. Population characteristics. Study population of 15,892 diabetic men 
from the Finnish Randomized Study of Screening for Prostate Cancer 
 
 Total Users of 
 Metformi
n 
Thiazolidinedione
s 
Insulin 
secretagogue
s 
Insulins 
N of men 15,892 12,440 1,819 8,116 6,270 
Median (IQR) 
age at baseline 
59 (55-
63) 
59 (55-
63) 
59 (55-63) 59 (55-63) 59 (55-
63) 
Median (IQR) 
follow-up after 
baseline 
17.0 
(13.0-
19.0) 
17.2 
(14.8-
19.0) 
18.0 (17.0-19.0) 17.0 (11.3-
18.7) 
17.0 
(11.9-
18.7) 
Median (IQR) 
BMI 
28.4 
(25.9-
31.3) 
28.7 
(26.2-
31.6)** 
28.8 (26.3-
32.1)** 
28.4 (26.0-
31.5) 
28.4 
(25.8-
31.5) 
N of deaths 
overall 
6,613 
(43.4%
) 
4,761 
(38.3%) 
475 (26.1%) 4,112 
(50.7%) 
3,192 
(50.9%) 
N of cancer 
deaths overall 
1.688 
(11.1%
) 
1,232 
(9.9%) 
165 (9.1%) 1,007 
(12.4%) 
775 
(12.4%) 
Lung cancer 
deaths 
355 
(2.3%) 
255 
(2.0%) 
36 (2.0%) 199 (2.5%) 148 
(2.4%) 
Colorectal 
cancer deaths 
152 
(1.0%) 
114 
(0.9%) 
20 (1.1%) 87 (1.1%) 49 
(0.8%) 
Pancreatic 
cancer deaths 
238 
(1.6%) 
165 
(1.3%) 
25 (1.4%) 143 (1.8%) 138 
(2.2%) 
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Stomach 
cancer deaths 
64 
(0.4%) 
46 
(0.4%) 
8 (0.4%) 45 (0.6%) 27 
(0.4%) 
Liver cancer 
deaths 
181 
(1.2%) 
147 
(1.2%) 
17 (0.9%) 130 (1.6%) 86 
(1.4%) 
Non-Hodgkin 
lymphoma 
deaths 
48 
(0.3%) 
32 
(0.3%) 
1 (0.1%) 28 (0.3%) 23 
(0.4%) 
Kidney cancer 
deaths 
53 
(0.3%) 
39 
(0.3%) 
6 (0.3%) 29 (0.4%) 26 
(0.4%) 
Urinary bladder 
cancer deaths 
36 
(0.2%) 
28 
(0.2%) 
3 (0.2%) 24 (0.3%) 17 
(0.3%) 
CNS cancer 
deaths 
27 
(0.2%) 
19 
(0.2%) 
5 (0.3%) 16 (0.2%) 17 
(0.3%) 
Use of other 
drug; n (%):) 
     
Statins* 11,323 
(74.3%
) 
9.708 
(78.0%) 
1,576 (86.6%) 5,918 
(72.9%) 
4,725 
(75.4%) 
Antihypertensiv
e drugs* 
14,253 
(93.5%
) 
11,750 
(94.5%) 
1,733 (95.3%) 7,670 
(94.5%) 
5,987 
(95.5%) 
NSAIDs* 13,546 
(88.9%
) 
11,268 
(90.6%) 
1,691 (93.0%) 7,111 
(87.6%) 
5,569 
(88,8%) 
Aspirin* 3,663 
(24.0%
) 
3,111 
(25.0%) 
476 (26.2%) 1,986 
(24.5%) 
1,611 
(25.7%) 
Anticoagulant 
drugs* 
8,231 
(54.0%
) 
6,896 
(55.4%) 
994 (54.6%) 4,459 
(54.9%) 
3,727 
(59.4%) 
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Median 
Charlson 
comorbidity 
score* 
0 (0-2) 0 (0-2) 0 (0-1) 1 (0-2) 1 (0
-
2) 
 
*P < 0.05 for difference between users of different drug groups 
** p for difference < 0.001 for metformin users compared to other 
drug groups; p = 0.003 for thiazoledenedione users compared to 
other drug groups 
 
 
4.2 Risk of cancer death by antidiabetic drug use 
  
 
Cancer mortality among metformin ever users was 8.2 deaths/ 1,000 person years, 
while among never users it was 16.4/1,000 person years. Use of metformin was not 
associated with the risk of cancer death in age-adjusted analysis (HR 1.00, 95%CI 0.88-
1.14), but in the multivariable-adjusted analysis, an increased risk compared to non-
users was observed (HR 1.13, 95%CI 1.00-1.28, Table 2).  Similarly, users of insulin 
secretagogues and insulins also had an elevated risk of cancer death compared to non-
users.  
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Table 2. Cancer mortality by antidiabetic drug use. Cohort of 15,244 diabetic men in the Finnish Randomized Study of Screening for 
Prostate Cancer 
 
   Mortality from 
  Cancer overall Lung 
cancer 
Colorectal 
ca 
Pancreat
ic ca 
Stomach 
ca 
Liver ca Non-
Hodgkin 
lymphom
a 
Renal 
cance
r 
Bladd
er 
cance
r 
Brain 
and CNS 
ca 
  Age-
adjuste
d 
analysi
s 
Multi-
variable 
adjusted 
Multi-
variable 
adjusted 
Multi-
variable 
adjusted 
Multi-
variable 
adjusted 
Multi-
variable 
adjusted 
Multi-
variable 
adjuste
d 
Multi-
variable 
adjusted 
Multi-
variabl
e 
adjust
ed 
Multi-
variabl
e 
adjust
ed 
Multi-
variable 
adjusted 
Antidiabeti
c 
medication 
use 
HR 
(95% 
CI) 
HR (95% 
CI) 
HR (95% 
CI) 
HR (95% 
CI) 
HR (95% 
CI) 
HR (95% 
CI) 
HR 
(95% 
CI) 
HR (95% 
CI) 
HR 
(95% 
CI) 
HR 
(95% 
CI) 
HR (95% 
CI) 
None Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref 
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Metformin 1.00 
(0.88-
1.14) 
1.13 
(1.00-
1.28) 
1.05 (0.80-
1.38) 
1.25 (0.82-
1.91) 
1.01 
(0.73-
1.40) 
1.05 
(0.56-
1.97) 
1.87 
(1.23-
2.83) 
0.70 
(0.35-
1.37) 
1.50 
(0.74-
3.06) 
1.54 
(0.62-
3.82) 
1.21 
(0.44-
3.31) 
Thiazolidin
ediones 
0.88 
(0.75-
1.04) 
0.95 
(0.81-
1.12) 
0.98 (0.68-
1.40) 
1.38 (0.85-
2.26) 
1.13 
(0.74-
1.74) 
1.27 
(0.59-
2.76) 
0.82 
(0.49-
1.37) 
0.17 
(0.02-
1.27) 
1.32 
(0.55-
3.21) 
0.74 
(0.22-
2.49) 
2.48 
(0.87-
7.11) 
Insulin 
secretagog
ues 
1.42 
(1.27-
1.59) 
1.40 
(1.26-
1.56) 
1.29 (1.02-
1.63) 
1.43 (1.01-
2.04) 
1.29 
(0.96-
1.74) 
2.53 
(1.40-
4.56) 
2.28 
(1.60-
3.26) 
1.56 
(0.83-
2.95) 
0.96 
(0.52-
1.78) 
1.85 
(0.85-
4.02) 
1.02 
(0.42-
2.50) 
Insulin 2.04 
(1.84-
2.27) 
2.16 
(1.95-
2.39) 
1.86 (1.49-
2.34) 
1.13 (0.79-
1.63) 
3.86 
(2.93-
5.07) 
1.70 
(1.01-
2.86) 
2.03 
(1.49-
2.76) 
2.18 
(1.19-
3.98) 
2.80 
(1.57-
5.00) 
2.01 
(1.00-
4.07) 
5.31 
(2.31-
12.23) 
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 In a separate analysis by cancer type, the risk increase among metformin users was 
significant only for liver cancer. Risk increase by insulin was observed for all cancer 
types, and risk increase by use of insulin secretagogues was similarly observed for all 
cancer types with the exception of renal cancer and tumors of the brain and the 
central nervous system. 
  
 
4.3 Risk trends by cumulative antidiabetic drug use 
  
 
Cancer mortality decreased in inverse association with years of metformin use. 
However, when analyzed by cancer type, this was driven mainly by pancreatic cancer: 
HR for pancreatic cancer death was 0.48 (0.28-0.84) among men who had used 
metformin for eight years or longer (Table 3). No significant risk lowering by years of 
metformin use were observed for other cancer types (Table 4). 
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Table 3. Cancer mortality by duration of antidiabetic drug use.  
  
  Mortality 
from 
    
  Cancer 
overall 
Lung 
cancer 
Colorectal 
ca 
Pancreatic 
ca 
Stomach 
ca 
Duration 
of use 
HR (95% 
CI) 
HR 
(95% CI) 
HR (95% 
CI) 
HR (95% 
CI) 
HR (95% 
CI) 
Metformin           
1-7 yrs 1.23 (1.08-
1.39) 
1.14 
(0.87-
1.49) 
1.25 (0.81-
1.93) 
1.21 (0.88-
1.66) 
1.08 (0.57-
2.03) 
8-10 yrs 0.92 (0.77-
1.11) 
0.83 
(0.56-
1.24) 
1.41 (0.80-
2.49) 
0.48 (0.28-
0.84) 
1.03 (0.41-
2.55) 
11 yrs or 
longer 
0.73 (0.60-
0.88) 
0.70 
(0.46-
1.07) 
0.91 (0.47-
1.74) 
0.47 (0.27-
0.79) 
0.74 (0.27-
2.03) 
Intensity of use, 
DDD/year 
    
1-91 1.37 (1.13-
1.66) 
1.04 
(0.66-
1.64) 
1.43 (0.76-
2.71) 
2.06 (1.33-
3.19) 
1.20 (0.44-
3.33) 
91-200 1.35 (1.16-
1.56) 
1.22 
(0.88-
1.69) 
1.33 (0.80-
2.21) 
1.22 (0.82-
1.81) 
1.01 (0.45-
2.28) 
200 or 
more 
0.97 (0.85-
1.11) 
0.97 
(0.72-
1.30) 
1.15 (0.72-
1.83) 
0.71 (0.49-
1.02) 
1.03 (0.52-
2.05) 
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Duration of 
use 
     
Insulin 
secretagogues 
          
1-4 yrs 1.64 (1.45-
1.87) 
1.65 
(1.25-
2.16) 
1.30 
(0.82-
2.05) 
1.86 
(1.34-
2.56) 
2.52 (1.27-
4.99) 
5-9 yrs 1.32 (1.15-
1.52) 
1.04 
(0.75-
1.43) 
1.60 
(1.02-
2.49) 
0.83 
(0.55-
1.26) 
3.09 (1.56-
6.13) 
10 yrs or 
longer 
1.10 (0.93-
1.30) 
1.06 
(0.74-
1.51) 
1.44 
(0.86-
2.40) 
0.96 
(0.61-
1.51) 
1.60 (0.63-
4.10) 
Intensity of 
use 
     
1-261 1.75 (1.53-
1.99) 
1.78 
(1.35-
2.33) 
1.60 
(1.03-
2.46) 
1.82 
(1.29-
2.56) 
2.73 (1.37-
5.44) 
261-487 1.28 (1.11-
1.48) 
1.06 
(0.77-
1.47) 
1.36 
(0.84-
2.18) 
1.27 
(0.87-
1.83) 
2.31 (1.10-
4.87) 
487 or more 1.10 (0.94-
1.27) 
0.92 
(0.66-
1.29) 
1.29 
(0.78-
2.11)  
0.77 
(0.50-
1.17) 
2.46 (1.16-
5.22) 
Duration of 
use 
     
Insulins           
1-4 yr 3.18 (2.82-
3.59) 
2.54 
(1.93-
3.34) 
1.34 
(0.84-
2.14) 
7.03 
(5.23-
9.45) 
2.30 (1.23-
4.30) 
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5-10 yrs 1.62 (1.39-
1.89) 
1.45 
(1.03-
2.05) 
1.10 
(0.65-
1.87) 
1.87 
(1.19-
2.94) 
1.46 (0.69-
3.08) 
11 yrs or 
longer 
1.31 (1.08-
1.60) 
1.39 
(0.93-
2.10) 
0.84 
(0.41-
1.70)  
1.51 
(0.85-
2.70) 
0.90 (0.27-
3.03) 
Intensity of 
use 
     
1-203 2.67 (2.38-
3.01) 
2.39 
(1.84-
3.11) 
1.15 
(0.73-
1.80) 
5.00 
(3.70-
6.77) 
2.86 (1.13-
5.00) 
203-408 1.67 (1.42-
1.97) 
1.49 
(1.03-
2.16) 
1.16 
(0.67-
2.03) 
2.62 
(1.70-
4.02) 
0.60 (0.18-
1.97) 
408 or more 1.28 (1.02-
1.60) 
1.11 
(0.66-
1.85) 
0.69 
(0.28-
1.70) 
1.61 
(0.86-
3.01) 
0.34 (0.05-
2.50) 
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Table 4. Cancer mortality by duration of antidiabetic drug use. 
 Mortality 
from 
    
 Liver ca Non-
Hodgkin 
lymphoma 
Renal 
ca 
Bladder 
ca 
Brain 
and 
CNS ca 
Duration of 
use 
HR (95% 
CI) 
HR (95% 
CI) 
HR 
(95% 
CI) 
HR (95% 
CI) 
HR 
(95% 
CI) 
Metformin      
1-3 yrs 1.93 (1.27-
2.94) 
0.73 (0.36-
1.49) 
1.58 
(0.78-
3.19) 
1.60 (0.64-
3.98) 
1.19 
(0.43-
3.29) 
4-6 yrs 1.50 (0.83-
2.69) 
0.69 (0.26-
1.81) 
1.37 
(0.51-
3.69) 
1.18 (0.30-
4.58) 
1.63 
(0.42-
6.39) 
7 yrs or longer 1.81 (1.01-
3.26) 
0.56 (0.20-
1.58) 
0.60 
(0.16-
2.16) 
1.47 (0.40-
5.41) 
0.69 
(0.13-
3.54) 
Intensity of 
use 
     
1-91 1.75 (0.93-
3.32) 
0.92 (0.30-
2.84) 
1.51 
(0.48-
4.76) 
1.74 (0.44-
6.87) 
- 
91-200 2.29 (1.42-
3.69) 
0.47 (0.17-
1.33) 
1.75 
(0.75-
4.08) 
2.12 (0.76-
5.89) 
1.88 
(0.59-
5.95) 
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200 or more 1.67 (1.07-
2.61) 
0.76 (0.36-
1.58) 
1.36 
(0.62-
2.99) 
1.19 (0.44-
3.23) 
1.15 
(0.38-
3.45) 
Duration of 
use 
     
Insulin 
secretagogues 
     
1-4 yrs 2.00 (1.30-
3.07) 
2.05 (0.99-
4.25) 
1.18 
(0.57-
2.43) 
1.04 (0.35-
3.13) 
1.49 
(0.56-
3.98) 
5-8 yrs 2.54 (1.66-
3.87) 
1.78 (0.82-
3.88) 
0.84 
(0.37-
1.90) 
3.09 (1.28-
7.46) 
0.90 
(0.30-
2.73) 
9yrs or longer 2.47 (1.53-
3.99) 
0.54 (0.15-
1.93) 
0.78 
(0.29-
2.06) 
1.61 (0.51-
5.11) 
0.45 
(0.09-
2.26) 
Intensity of 
use 
     
1-261 2.29 (1.48-
3.53) 
2.46 (1.23-
4.95) 
1.25 
(0.59-
2.66) 
1.67 (0.61-
4.53) 
1.79 
(0.67-
4.81) 
261-487 1.93 (1.23-
3.04) 
1.05 (0.42-
2.61) 
1.09 
(0.51-
2.33) 
2.25 (0.89-
5.66) 
0.99 
(0.33-
2.97) 
487 or more 2.68 (1.74-
4.12) 
0.94 (0.36-
2.43) 
0.55 
(0.22-
1.38) 
1.63 (0.59-
4.50) 
0.40 
(0.10-
1.61) 
Duration of 
use 
     
21 
 
Insulins      
1-3 yr 2.28 (1.55-
3.34) 
4.09 (2.05-
8.13) 
5.30 
(2.84-
9.89) 
2.38 (1.00-
5.65) 
8.47 
(3.36-
21.36) 
4-8 yrs 2.06 (1.36-
3.11) 
1.80 (0.75-
4.29) 
1.09 
(0.37-
3.20) 
1.89 (0.73-
4.94) 
3.18 
(0.97-
10.49) 
9 yrs or longer 1.44 (0.78-
2.64) 
0.58 (0.13-
2.51) 
1.00 
(0.23-
4.40) 
1.51 (0.41-
5.50) 
3.17 
(0.63-
15.87) 
Intensity of 
use 
     
1-203 1.91 (1.30-
2.80) 
2.99 (1.50-
5.94) 
4.58 
(2.24-
8.69) 
1.80 (0.72-
4.47) 
10.81 
(4.46-
26.21) 
203-408 1.89 (1.20-
2.98) 
1.91 (0.76-
4.79) 
2.16 
(0.86-
5.38) 
1.87 (0.67-
5.21) 
- 
408 or more 2.21 (1.30-
3.75) 
1.04 (0.24-
4.46) 
0.54 
(0.07-
4.04) 
3.02 (1.09-
8.37) 
3.11 
(0.67-
14.46) 
 
Among users of sulphonylureas and insulins the risk of cancer death was elevated 
especially during the first years of usage. The risk increase attenuated in continued 
use, but the risk estimates remained elevated compared to men with diabetes not 
using these drugs (Table 3). 
  
 
4.4 Lag-time analyses 
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In lag-time analysis, the decreased risk of pancreatic cancer death observed among 
metformin users disappeared. Rather, use of metformin was associated with an 
increased risk of cancer death for all cancer types similar to insulin and insulin 
secretagogues (Table 5). 
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Table 5. Lag-time analyses 
  
Mortality from           
  Cancer 
overall 
Lung 
cancer 
Colorectal 
ca 
Pancreatic 
ca 
Stomach 
ca 
Liver ca Non-
Hodgkin 
lymphoma 
Renal ca Bladder 
ca 
Brain 
and 
CNS ca 
Antidiabetic 
medication 
use 
HR 
(95%) 
HR 
(95% 
CI) 
HR (95% 
CI) 
HR (95% 
CI) 
HR (95% 
CI) 
HR 
(95% 
CI) 
HR (95% 
CI) 
HR (95% 
CI) 
HR 
(95% CI) 
HR 
(95% 
CI) 
  None          
  1 year lag time         
None Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref 
Metformin 1.26 
(1.11-
1.43) 
1.07 
(0.82-
1.40) 
1.48 
(0.97-
2.27) 
1.10 
(0.80-
1.52) 
1.05 
(0.56-
1.96) 
2.03 
(1.35-
3.06) 
0.92 
(0.46-
1.84) 
1.61 
(0.79-
3.27) 
1.83 
(0.73-
4.61) 
1.57 
(0.57-
4.36) 
Insulin 
secretagogues 
1.45  
(1.30-
1.61) 
1.41 
(1.11-
1.78) 
1.43 
(1.00-
2.04) 
1.38 
(1.03-
1.85) 
2.68 
(1.50-
4.80) 
2.33 
(1.64-
3.32) 
1.18 
(0.63-
2.21) 
1.15 
(0.62-
2.12) 
1.81 
(0.82-
3.96) 
1.02 
(0.42-
2.46) 
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Insulin 1.76 
(1.59-
1.96) 
1.49 
(1.18-
1.89) 
1.11 
(0.77-
1.61) 
2.51 
(1.92-
3.30) 
1.34 
(0.78-
2.30) 
1.78 
(1.30-
2.43) 
1.70 
(0.91-
3.17) 
1.83 
(1.01-
3.31) 
2.24 
(1.11-
4.53) 
3.13 
(1.39-
7.03) 
  3 years lag time         
None Ref Ref Ref Ref Ref Ref Ref Ref Ref Ref 
Metformin 1.27 
(1.12-
1.43) 
1.20 
(0.92-
1.56) 
1.79 
(1.18-
2.74) 
0.82 
(0.60-
1.12) 
1.24 
(0.67-
2.30) 
2.24 
(1.50-
3.33) 
1.05 
(0.52-
2.11) 
1.73 
(0.87-
3.46) 
1.64 
(0.68-
3.96) 
1.39 
(0.51-
3.74) 
Insulin 
secretagogues 
1.33 
(1.20-
1.49) 
1.21 
(0.95-
1.53) 
1.27 
(0.89-
1.81) 
1.27 
(0.95-
1.70) 
2.38 
(1.34-
4.23) 
2.05 
(1.44-
2.91) 
1.10 
(0.58-
2.07) 
1.27 
(0.68-
2.35) 
1.74 
(0.80-
3.78) 
0.76 
(0.31-
1.86) 
Insulin 1.31 
(1.17-
1.47) 
1.24 
(0.96-
1.60) 
0.96 
(0.65-
1.44) 
1.06 
(0.76-
1.46) 
1.28 
(0.72-
2.27) 
1.88 
(1.37-
2.58) 
1.18 
(0.59-
2.36) 
1.29 
(0.68-
2.46) 
2.02 
(0.98-
4.15) 
1.31 
(0.50-
3.40) 
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Elevated risk of cancer death among users of sulphonylureas and insulins remained for 
most cancer types in 1-year lag-time analysis, whereas in the 3-year lag time analysis 
the risk increase was no longer observed for colorectal and pancreatic cancer (Table 
4). 
 
 
4.5 Subgroup analyses 
 
 
Use of other drugs affected the risk of cancer death mainly in users of insulin 
secretagogoues; the risk increase among users of this drug group was ameliorated by 
concomitant use of aspirin (p for interaction 0.022), cholesterol-lowering statins (p for 
interaction 0.002) and anticoagulant drugs (p for interaction < 0.001) (Figure 2). 
Similarly, use of other drug groups slightly lowered the observed risk estimates among 
insulin users. 
 
 
 
Figure 2. Cancer mortality in users of insulin secretagogues, a stratified 
subgroup analysis 
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BMI and HbA1c did not have a clear effect modification on risk association between 
ADM use and risk of cancer death. BMI modified the risk association only among users 
of glitazones; cancer mortality was increased among glitazone users compared to non-
users only in the subgroup of men with BMI less than 27 kg/m2 (p for interaction 
0.037). 
 
 
4.6 Sensitivity analyses 
 
 
We run a sensitivity analyses with new user design, where we excluded men who had 
recorded use of any ADMs before baseline. Results were generally similar as in the 
main analysis, but the risk association between insulin use and risk of cancer death 
became stronger for overall cancer mortality (HR 2.96, 95% CI 2.59-3.37), pancreatic 
cancer (HR 7.02, 95% CI 5.09-9.68) and kidney cancer (HR 4.86, 95% CI 2.25-10.48).  
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6. Discussion 
 
 
  
We found that among men with diabetes, use of insulin and insulin secretagogues are 
linked to a higher risk of cancer death. Our results support a role of hyperinsulinemia 
as a risk factor for cancer death. The increased risk was associated also with metformin 
users, although the risk increase was smaller. This suggests that poor glycemic control 
or advanced diabetes, which requires extensive medication use, could be a risk factor 
for cancer death. The risk increase among insulin users remained in lag time analyses 
for up to three years after the actual usage suggesting a long-term risk connection. 
An association of diabetes with cancer incidence and mortality has previously 
been demonstrated by many studies[1,2]. There are several explanations for 
the association. Diabetes and cancer have common risk factors, for example 
obesity, some dietary patterns and a sedentary lifestyle[13,14]. In our subgroup 
analysis, BMI did not show significant effect modification on the risk association 
between anti-DM drug use and cancer mortality, though the statistical power 
was limited.  Other possible links may be effects of hyperglycemia[15], 
hyperinsulinemia, anti-diabetic medication or combination of these risk 
factors[14]. 
Our study supports hyperinsulinemia as a risk factor for cancer death, as we found that 
use of insulins and drugs increasing insulin secretion was connected to a higher cancer 
mortality compared to diabetic men not using these drugs. These medications increase 
circulating insulin levels, which affects cancer cell growth, proliferation and resistance 
to apoptosis in vitro[16,17]. Hyperinsulinemia may also be connected with 
development of more aggressive cancer types[18] and may promote development of 
many cancers, for example colon cancer[19,20], skin cancer[21,22], breast cancer[23], 
prostate cancer[24], lung cancer[25,26], liver cancer[27] and pancreatic cancer[28]. 
Insulin-like growth factors have also been linked to risk of cancer and cancer 
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death[29,30]. Diabetes decreases serum IGF-I levels and use of insulin or 
sulphonylureas restores them.[31]  
Some studies have reported that sulphonylureas decrease growth of cancer cells in 
vitro[32]. However, epidemiological evidence suggests the contrary: sulphonylureas 
have been linked with an increased risk of advanced prostate cancer[7,33]. Other 
studies have found no difference in risk of cancer when comparing sulphonylurea 
users to metformin users[34,35], but the risk has been reported to be lower among 
users of insulin sensitizers when compared to insulin secretagogues[36]. Thus, the 
increase in insulin secretion during use of sulphonyureas and other insulin 
secretagogues may have greater importance regarding cancer mortality than any 
direct effects sulphonylureas may have on cancer cells. 
Our results are not concordant with previous studies linking metformin use with 
decreased overall cancer risk and mortality[5,37-40]. Some retrospective analyses 
suggest that metformin increases the effectiveness of chemotherapy[6,41,42]. 
Metformin has been suggested to affect cancer cell growth by reducing stimulus from 
insulin and IGF-1, blocking of the PI3K/Akt/mTOR signaling pathway and inhibition 
of cell division[4]. However, we did not observe association between metformin and 
cancer mortality among diabetic men. One explanation to this might be that the risk-
decreasing effects of metformin are masked by risk-increasing effects of diabetes. To 
our knowledge, this is the first study to estimate long-term risk association, as well as 
simultaneous use of other antidiabetic drugs and dose-dependence with metformin 
use. 
Strengths of our study were large population-based study population, detailed, 
reliable information on quantity and timing of ADM use, which made it possible to 
evaluate effects of different ADM groups while taking into account simultaneous use 
of multiple drug groups. 
Study weaknesses were that we did not have comprehensive information of BMI or 
blood glucose levels, although in subgroup analysis we had limited ability to evaluate 
them. These may have been confounding factors. We also did not have information 
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on lifestyle habits such as smoking, exercise or diet or indicators of SES such as 
education. These may also have been confounding factors. We did not have data on 
type of diabetes or total disease duration apart from medication use and recorded 
diagnoses. We did not have detailed data on patient characteristics to account for 
differences in indications of various ADMs. 
 In conclusion, we found that use of antidiabetic drugs in general, but especially 
insulins and insulin secretagogues are linked to increased risk of cancer death. The 
increased risk is related to beginning of usage and attenuates in long-term, supporting 
the notion that risk increase is greatest in the beginning of usage, i.e. likely to be 
caused by underlying untreated diabetes. Risk attenuation in long-term suggests that 
proper diabetes management may lower the oncological risks associated with 
untreated diabetes. Metformin’s possible shielding effects were not confirmed in this 
analysis. 
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